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Abstract: The increasing number of papers in which bioconjugates of oligo- and/or 
polypeptides are present indicates the importance and potential of these constructs. In this 
contribution there is an attempt to provide an overview of our results concerning the 
preparation, functional characterization and mainly biomedicinal application of conjugates 
with chemotherapeutic agents against tumour, infectious diseases, with T-cell epitope 
peptides or with “reporter” entities to be used also for mechanistic studies prepared in our 
laboratories last decades.   
 
 
Introduction 
 
During the last two decades cellular targeting by peptide-based bioconjugates resulted in 
novel approaches for which various drugs, reporter entities or even epitopes were attached to 
appropriate structures
1-4
. These two- or three-component constructs are widely utilized for 
biomedical research studying their potential to eliminate selectively tumor cells, intracellular 
microbes or to study uptake mechanisms or changes in protein expression profiles. The 
partner molecules are attached by covalent bond and preserve relevant functional properties 
(like biological activity or „reporter properties”) after conjugation (Figure 1.) 
 
Figure 1: Peptide/polypeptide/protein based bioconjugates. 
With selected examples here we outline our findings derived from novel two- or three-
component conjugates of antitumour/antimicrobial compound (e.g. daunomycin [Dau] 
5-12
, 
methotrexate [MTX] 
13-20
, vinblastine
21
, ferrocene derivatives
22
 or antitubelculars
23-25
), 
enzyme (e.g. calpain) activator/substrate 
26, 27
 linear T-cell epitope peptides 
28- 32
 or “reporter” 
molecules (e. g. radioligand 
33-37
, fluorophore 
38-41
)
 
(Figure 2). 
 
 
Figure 2: Structure of examples of drugs (daunomycin, methotrexate, vindoline and ferrocene 
derivatives), linear T-cell epitope peptide from M. tuberculosis and of “reporter” entities 
[5(6)-carboxyfluorescein (Cf) and diethylene-triamine pentaacetic acid (DTPA) chelator] used 
as partner for conjugation. 
 
As peptide-partner component of the bioconjugates (a) novel branched chain polymeric 
polypeptides
 5-8, 11, 13-15, 17, 20, 28-31, 33-37, 40, 41 
with different side chain structure, charge 
properties, and solution conformation were designed, (b) well-established or newly 
discovered oligopeptide with specific recognition unit, like cell surface-receptor binding 
ligand (e.g. Erb-B2
12
, MHC for T-cell epitope
 23-25, 
 or (c) cell penetrating peptides [CPP] (e.g. 
oligoarginine, penetratin)
 9, 10, 18, 21, 22, 26, 27
 were chosen for construction of targeting 
bioconjugates (Figure 3) 
 
 
 
 
 
 
 
 
 
Figure 3: Peptide/polypeptide component of the bioconjugates for targeting: branched chain 
polymeric polypeptides, oligotuftsin (T20), sequential oligopeptide carrier (SOC) (a), cell 
surface-receptor binding ligand (e.g. Erb-B2), linear T-cell (MHC-II), B-cell epitope 
(b) or cell penetrating peptides (e.g. oligoarginine, penetratin) (c).  
. 
MTX-conjugates with new, potential chemotherapeutic properties against cancer cells 
and intracellular parasite Leishmania donovani   
 
Pentaglutamylated methotrexate conjugates with cell penetrating oligopeptides 
 
A folate antagonist (MTX) or its pentaglutamylated (MTX-Glu5) derivative was conjugated 
with cell-penetrating oligopeptides (penetratin or octaarginine) with or without tetrapeptide 
spacer unit (GFLG). 5(6)-carboxyfluorescein (Cf) labelled derivatives were also prepared
18
.  
 
The in vitro cytostatic activity and cellular-uptake of conjugates were studied on breast 
carcinoma cells (on MDA-MB-231 as resistant and on MCF-7 as sensitive cells). Although 
the presence of Glu5 moiety significantly decreased the level of internalisation, but all 
conjugates were able to penetrate - to some extent - into both cell types. However, only the 
conjugates of penetratin showed in vitro cytostatic activity. The most effective conjugates 
include MTX-Glu5-Penetratin(desMet) and MTX-Glu5-GFLG-Penetratin(desMet) containing 
a tetrapeptide spacer unit. The latter one was effective on both cell cultures, while the former 
compound was active only on the resistant tumour cells. 
 
 
 
 
 
Figure 4: Schematic route of cellular uptake and mechanism of action of methotrexate 
(MTX), pentaglutamylated MTX (MTX-Glu5) and pentaglutamylated MTX – cell penetrating 
peptide conjugate (MTX-Glu5-CPP) 
18, 42, 43
  
 
Our results suggest that the translocation of polyglutamylated MTX could be dependent on 
the structure of the CPP (penetratin desMet vs Arg8) as well as on the spacer between the 
partners. In conclusion the intracellular delivery of MTX-Glu5-may be a new avenue to treat 
resistant tumors
19
.  
 
Methotrexate conjugates with branched chain polymeric polypeptides 
  
Considering the inhibitory potential of MTX against a group of intracellular parasites 
(Leishmania) of macrophages causing leishmaniasis in man
44,45
 we have prepared MTX 
conjugates with branched chain polymeric polypeptides 
13-15
.   
 
We have demonstrated with a set of structurally related branched polypeptides (Figure 5) that 
the side chain composition and amino acid sequence could markedly determine the physico-
chemical characteristics including solution conformation, as well as the cytotoxicity, blood 
clearance, biodistribution and even the interaction with phospholipid mono- or bilayers of the 
compound 
46-49
  
 
 
Figure 5: Schematic structure of XAK type branched chain polymeric polypeptide with 
poly[L-Lys] backbone. K = Lys, A = Ala, X = E (Glu), Ac-E (Ac-Glu), Suc-E (Suc-Glu), L 
(Leu), S (Ser), or O (Orn).  
 
Similarly, in conjugates the functional characteristics of the covalently attached moiety are 
highly influenced by the properties of the macromolecular carrier component (Figure 5). 
Conjugates with various chemotherapeutic drugs (e.g. Dau
5,6
, MTX
13
, GnRH antagonist
50,51
, 
amiloride
52
 or with several radionuclides
34-37
 were prepared and tested for antitumour effect or 
imaging efficacy.  
 
In order to investigate the potential of branched chain polymeric polypeptides for MTX 
targeting to Leishmania donovani infected macrophages proliferating intracellularly, a new set 
of conjugates with amphoteric (EAK) or polycationic (AK, SAK, ALK) (Figures 5 and 6a) 
polypeptide was prepared
14,15
 and the leishmanicid activity was tested in collaboration with 
A.C. Ghose et al. at the Bose Institute in Kolkata.  
 
The effect of these conjugates has been studied and compared with that of the free 
drug/carrier and the non-covalent mixture of the two partners in mouse macrophages in vitro 
as well as in vivo in L. donovani infected in BALB/c mice. Among conjugates studied, MTX 
attached to polycationic ALK (MTX-ALK) exhibited pronounced anti-parasite activity both 
in vitro (Figure 6b) and in vivo (Figure 6c). 
 
Figure 6: Schematic structure of branched chain polymeric polypeptide ALK and MTX (a), 
the in vitro (b) and in vivo effect of the conjugate (MTX-ALK), free MTX, free polypeptide 
(ALK) and of the mixture of ALK+MTX treatment of L. donovani infected macrophages (b) 
or BALB/c mice (c).  
 
Chemotactic responses could play a significant role during the course of parasite–host–cell 
interaction, and also in Leishmania differentiation. Therefore MTX attached to XAK type 
polypeptides (X=Ser, SAK or X= Glu, EAK) (Figure 5) by thioether linkage with/without 
GFLGC oligopeptide spacer were investigated for anti-Leishmania braziliensis parasite effect, 
cytotoxicity/cytostatic as well as chemotactic properties under in vitro conditions. Data 
suggest that chemotaxis produced by the MTX-XAK polypeptide conjugates depends on 
specific chemical characteristics. For example, the identity of the N-terminal amino acid (X= 
Ser vs. Glu) in the branch and also the attachment site of MTX in the conjugates (- vs. -
carboxylic groups) significantly influences the elicited chemotaxis. Specific 
cytotoxic/cytostatic effects of the conjugates on parasites/murine and human cells of the 
macrophage/monocyte system respectively, suggest that these MTX-conjugates can be 
considered as selective compounds for Leishmania
17
. 
 
Recently, a new group of XAK type branched polypeptides with side chain terminal X = Ile, 
Nle, Leu, Val, or Arg amino acid
53
 and their MTX-conjugates with amide linkage were 
synthesized
20
 using optimized procedures. All XAK polypeptides with hydrophobic amino 
acid (Ile, Nle, Leu or Val) were essentially non-toxic on murine bone marrow-derived 
macrophages from Balb/c mice, whereas the polypeptide with terminal Arg (RAK) proved to 
be markedly cytotoxic
20
.  
 
Oligopeptide conjugates with new, potential chemotherapeutic properties against cancer 
cells  
 
In addition to the biologically active pentaglutamylated MTX – CPP conjugates (see above) 
our research group reported on the synthesis of new, small or medium size oligopeptide-
antitumour compound conjugates
54
 with targeting of specific cell surface structures (e.g. Erb-
B2 receptor
12
, GnRH-III 
55-58
 or selectin
59
) and/or cell penetrating properties (e.g. 
oligoarginine 
9,10,18,21,22,59
, penetratin 
18,26
). In case of the most active conjugates promising 
first studies were performed to understand the mechanism of action (e.g. effect on the tubulin 
system 
21
, analysis of the conjugate induced protein expression profile. 
12,57 
 
 
Recently, a new set of vindoline derivatives, amino acid conjugates were prepared
60
. and 
selected derivatives, Br-vindoline-(L/D)-Trp, were coupled with octaarginine cell penetrating 
peptide at the N-terminal with amide bond.
61
 In vitro cytotoxic/cytostatic properties of 
vindoline derivatives studied on human leukemia cells (HL-60) suggested that in contrast to 
free vindoline different modifications of the ring system and/or the conjugation with L- or D-
Trp result in active compounds (IC50 = 25-80 µM)
58
. The conjugation of the Br-vindoline 
derivatives increased significantly the in vitro antitumor activity on HL-60, MCF-7 and 
MDA-MB-231 cells. However, in vivo the Br-vindoline-(L)-Trp-Arg8 conjugate could inhibit 
the tumour growth but none of the conjugates increased the survival of mouse leukaemia 
(P388) and murine colon carcinoma (C26) bearing mice in vivo
61
. 
 
In order to understand the differences between the efficacy of antitumour effect of free and 
oligopeptide conjugated drug at cellular level, we have investigated the protein expression 
profiles of an appropriate cell line after optimized treatment with the free or conjugated drug. 
For these studies Dau, a DNA-binding antineoplastic agent applied in the treatment of various 
types of cancer, like osteosarcomas and acute myeloid leukemia was selected (Figure 7).  
 
As demonstrated earlier the covalent coupling of Dau with branched polypeptide or 
oligopeptide carrier could improve its selectivity, decrease the side effects as well as alter the 
drug uptake and intracellular fate. In a novel pairs of conjugate Dau was attached to ErbB2 
receptor peptide ligand (LTVSPWY) for targeting cancer cells expressing ErbB2 receptor
12
 or 
to oligoarginine
9,10
. 
 
First, in vitro cytostatic effect and cellular uptake of Dau=Aoa-LTVSPWY-NH2 conjugate 
were studied on human cancer cell lines expressing different levels of ErbB2 receptor. The 
conjugate had the highest cytostatic effect as well as the most marked cellular uptake on HL-
60 cells  
 
  
Figure 7: Structure of free Dau and of Dau-conjugate with ERbB2 receptor ligand peptide 
(LTVSPWY) (a), the protein expression profile of free Dau-treated (b) and of Dau=Aoa-
LTVSPWY-NH2 conjugate-treated (c) HL-60 cells. Numbers show the significantly different 
spots on the gel after treatment for 24 h.   
 
We compared the protein expression profile of treated and non-treated HL-60 human 
leukemia cells and also of conjugate vs. free Dau treated cells. We have observed that the 
expression levels of several proteins were altered due to the treatment with the conjugate or 
with the free drug (Dau) in comparison with proteins from untreated cells (Figure 7). 
 
Proteomic analysis suggests that the expression of cytoskeletal, metabolic proteins and 
proteins involved in signalling processes were altered
12
: three proteins, whose expression was 
lower (tubulin beta chain) or markedly higher (proliferating cell nuclear antigen and protein 
kinase C inhibitor protein 1) after administration of cells with Dau-conjugate vs. free drug. 
Comparison of the protein expression profile of HL-60 cells was found to be dependent not 
only on the conditions (e.g. concentration selected for treatment: IC25, IC 37.5 and IC50 values), 
but also on the peptide component (Erb2 receptor ligand vs. cell penetrating oligoarginine 
[data not shown]). 
 
It should be mentioned that similar studies were performed with another conjugate composed 
of GnRH-III oligopeptide, as targeting ligand and Dau
 57
. The results of proteomic analysis 
reported could be utilized not only for clarification of mechanism of action of bioconjugates, 
but also for target identification and/or validation. 
 
 
Conjugates with “reporter” function including intracellular enzyme substrate or 
established/newly designed fluorophore for the analysis of cellular uptake and 
intracellular activities 
 
Cellular uptake mechanism and intracellular localization of conjugates as well as the cellular 
response activities of the attached „cargo” entities could be analysed by using labelled 
compounds. Here we summarise our results related to branched chain polymeric polypeptides 
and also cell penetrating peptide - enzyme substrate/activator conjugates.  
Analysis of the cellular uptake mechanism of branched chain polypeptides labelled by 
fluorophore  
Selective delivery of chemotherapeutic drugs (e.g. MTX, Dau) or radionucleide
36,37
, or 
epitope peptide
29 
into infected macrophages, tumour or antigen presenting cells, respectively 
could be a promising approach for improved therapies.  
MTX conjugate with branched chain polypeptides exhibited pronounced anti-Leishmania 
activity in vitro and in vivo as mentioned above
14,15
. Polypeptide conjugated Dau treatment of 
tumour bearing mice proved to be markedly pronounced
6
. However, these effects were very 
much dependent of the structural characteristics of the branched chain polypeptide partner of 
the bioconjugates used.  
In order to identify structural requirements for efficient transcellular delivery of branched 
polypeptides, we have studied murine bone marrow culture-derived macrophages (BMM) 
from 129/ICR mice after incubation with amphoteric (EAK) (Figure 5), and two polyanionic 
polypeptides differing in negative charge density: Ac-EAK has one negative charge per unit, 
while Suc-EAK bears two negative charges per unit under physiological conditions. In order 
to characterize the translocation, polypeptides with closely related topography were labelled 
with Cf 
40
 (Figure 8a). 
We found that this internalization process is dependent on experimental conditions (e.g. 
polypeptide concentration, (Figure 8b), temperature, (Figure 8c) and incubation time (Figure 
8d) applied during the treatment. The polyanionic polypeptide with high charge density (Suc-
EAK) translocated more efficiently under identical circumstances than AcEAK, which had a 
lower negitive charge density, while the amphoteric compound (EAK) were ingested only at 
limited level. Using macrophages from wild-type (SR-A) and class-A scavenger receptor 
knockout (SR-A-/-) mice, as well as specific inhibitors we demonstrated that SR-A is 
involved in the endocytosis of synthetic polyanionic polypeptides, especially Suc-EAK.  
Similar findings were reported on the uptake properties of these polyanionic polypeptides by 
murine macrophage-like cell line J774
41
. Thus, polypeptide with multiple negative charges 
seems to be appropriate as a macromolecular carrier for specific drug delivery into 
macrophages and these compounds could be considered as basis for development of further 
carriers and bioconjugates. 
 Figure 8: Schematic structure of carboxyfluorescein labelled XAK type branched chain 
polypeptides with poly[L-Lys] backbone (a), and the cellular uptake as a function of 
concentration (b), time (c) and temperature (d). K = Lys, A = Ala, X = E (Glu), Ac-E (Ac-
Glu) or Suc-E (Suc-Glu).  
For comparative analysis three polycationic branched chain polypeptides with different side 
chain structure XAK (X = Ser, SAK) (Figure 5) and XiK (X = Pro) were also labeled by Cf 
and analysed under the same conditions. Data indicated that the uptake characteristics of 
murine J774 macrophage cells were dependent of the side chain length and composition. 
Polypeptide with a single amino acid in the branches (PiK) was internalized mostly, but the 
uptake of SAK with longer side chain terminated by Ser residue, was significant only at the 
highest concentration studied in these in vitro experiments
41
.  
 
Considering that branched chain polypeptides with chemotherapeutic drugs (e.g. Dau, MTX) 
exerted significant antitumour activities in vitro
5, 13
, internalization studies of polypeptides 
were also conducted by tumour cell lines as well.  
 
The uptake and cellular localization studies were performed on tumour cell lines (HT-29, 
human colon carcinoma, HepG2, human hepatocellular carcinoma) and an extended group of 
polycationic branched chain polypeptides with Cf reporter moiety.
62 
This includes XAK (X = 
Ser, Arg, Ser, Thr), (Figure 5), AXK (X = Leu), XiK (X = Pro, Leu, His) types of architecture 
and poly[Lys], as control.  
 
In the case of HT-29 cells, the efficacy of the uptake, based on calculated fluorescence mean 
data normalized to Cf content was the following: Cf-HiK > Cf-LiK > Cf-RAK ∼ Cf-SAK > 
Cf-poly[Lys] > Cf-ALK at 50 μg/mL. The internalization profile of HepG2 cells was slightly 
different as follows: Cf-LiK > Cf-RAK > Cf-HiK > Cf-poly[Lys] > Cf-ALK. The comparison 
of the uptake by the two tumour cell lines indicates some similarities. Namely, the most 
engulfed three polypeptides (Cf-LiK, Cf-HiK, and Cf-RAK) and the least ingested 
polypeptides (Cf-PiK, Cf-TAK) were identical. (Essentially no (Cf-TAK) or negligible (Cf-
PiK) uptake was observed on either of the cell cultures.)
 62
 
 
In conclusion, the translocation is very much dependent on the side chain length, identity of 
amino acid X and on the distance between the poly[Lys] backbone and the terminal positive 
charge. It is important to emphasize that the engulfment by the cell lines is not necessarily the 
same. For example polypeptide PiK was transported into J774 macrophage cell efficiently, but 
it was only taken up at low level by the two tumour cell lines. Our findings using a wide set of 
relevant inhibitors also suggest that macropinocytosis and caveole/lipid raft mediated 
endocytosis are typically involved in the uptake of the cationic polymeric polypeptides. 
 
Cellular uptake and intracellular cleavage of the cell penetrating conjugate of calpain 
substate peptide labelled by fluorophor(s)  
For the analysis of the intracellular activity of calpain in vivo a novel substrate 
62
 of the 
enzyme was designed, prepared and covalently attached to cell penetrating peptide 
(oligoarginine) and conjugated with two fluorophores acting as FRET partners (Figure 9a.)
 27
 
It should be noted that the in both constructs (free and conjugated substrates) the necessary 
distance between the two FRET partners was preserved.  
 
First, the substrate properties of the new constructs were verified by using isolated, cell-free 
calpain B enzyme. Not only the labelled free substrate, but also the conjugated derivative 
maintained the substrate properties. In order to study the translocation properties of the free 
and conjugated peptides, the differential internalization was demonstrated in COST-7 cells by 
fluorescent microscopy experiments. In contrast to the free, labelled peptide (Dabcyl-
TPLKSPPPSPR-EDANS), its heptaarginine conjugate, substrate conjugate (Dabcyl-
TPLKSPPPSPRE(EDANS)RRRRRRR-NH2) exhibited high and homogeneous fluorescence in 
cells
27 (Figure 9b.) Thus with the introduction of fluorescent labels it was possible to 
demonstrate that the - enzyme substrate-conjugate retained the properties of the attached 
partners, namely the enzyme substrate related activity (specific cleavability by calpain) and 
the capability to enter the cell.  
 
For the verification of substrate to be cleaved by intracellular calpain, the substrate conjugate 
was added to the lysate of Drosophila melanogaster S2 cells and the calpain activity was 
determined. It was observed that the fluorescence intensity was changed indicating that 
substrate conjugate was functioning in the cell lysate, which could be inhibited by Calpain 
inhibitor I (Figure 9c.)
 27 
 
Results derived also from similar studies using cell penetrating peptide – calpain enzyme 
activator/inhibitor
26
 conjugates strongly indicate that this new cell-penetrating conjugates 
could be useful for determining as well as up or down-regulating intracellular calpain activity 
in cell lysate or in intact living cells of various origins. 
 
Figure 9: Structure of calpain substrate – heptaarginine (CPP) conjugate labelled with two 
FRET-partner fluorophores [N-terminal Dabcyl and EDANS attached to the side chain of Glu 
(E)] (a), internalization of the free and CPP-conjugated substrates by COST cells (b), cleavage 
of the labelled substrate-CPP conjugate by calpain in S2 cell lysate with/without Ca
2+
 and 
specific enzyme inhibitor (c).  
Conclusions 
 
Bioconjugation chemistry could represent a special and highly multidisciplinary field of 
organic chemistry. For the design of the chemical reaction strategy one has to consider the 
basic requirement: the partners must preserve their functional properties after the completion 
of the synthesis and purification. In peptide/polypeptide based bioconjugates the functional 
properties could mean bioactivity (e.g. recognition properties, cellular uptake, intracellular 
trafficking, biodistribution) as well as “reporter” properties (e.g. fluorescence).  
 
We found that the chemical structure of the targeting peptide partner, the topology of the 
attached entities as well as the nature of the linkage inserted have marked effects on binding 
(recognition) properties, intracellular targeting and subcellular distribution as well as cellular 
responses (e.g. cytostasis/cytotoxicity, protein expression profile) detected.   
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Figure legends 
 
Figure 1: Peptide/polypeptide/protein based bioconjugates 
 
Figure 2: Structure of examples of drugs (daunomycin, methotrexate, vindoline and ferrocene 
derivatives), linear T-cell epitope peptide from M. tuberculosis and of “reporter” entities 
[5(6)-carboxyfluorescein (Cf) and diethylene-triamine pentaacetic acid (DTPA) chelator] used 
as partner for conjugation. 
 
Figure 3: Peptide/polypeptide component of the bioconjugates for targeting: (a) branched 
chain polymeric polypeptides, oligotuftsin (T20), sequential oligopeptide carrier (SOC), (b) 
cell surface-receptor binding ligand (e.g. Erb-B2), linear T-cell (MHC-II), B-
epitope or (c) cell penetrating peptides (e.g. oligoarginine, penetratin).  
 
Figure 4: Schematic route of cellular uptake and mechanism of action of methotrexate 
(MTX), pentaglutamylated MTX (MTX-Glu5) and pentaglutamylated MTX – cell penetrating 
peptide conjugate (MTX-Glu5-CPP) 
18, 42, 43
  
 
Figure 5: Schematic structure of XAK type branched chain polymeric polypeptide with 
poly[L-Lys] backbone. K = Lys, A = Ala, X = E (Glu), Ac-E (Ac-Glu), Suc-E (Suc-Glu), L 
(Leu), S (Ser), or O (Orn).  
 
Figure 6: Schematic structure of branched chain polymeric polypeptide ALK and 
methotrexate (MTX) (a), the in vitro (b) and in vivo effect of the conjugate (MTX-ALK), free 
MTX, free polypeptide (ALK) and of the mixture of ALK+MTX treatment of L. donovani 
infected macrophages (b) or BALB/c mice (c).   
 
Figure 7: Structure of free Dau and of Dau-conjugate with ERbB2 receptor ligand peptide 
(LTVSPWY) (a), the protein expression profile of free Dau-treated (b) and of Dau=Aoa-
LTVSPWY-NH2 conjugate-treated (c) HL-60 cells. Numbers show the significantly different 
spots on the gel after treatment for 24 h 
 
Figure 8: Schematic structure of 5(6)-carboxyfluorescein labelled XAK type branched chain 
polypeptides with poly[L-Lys] backbone (a), and the cellular uptake as a function of 
concentration (b), time (c) and temperature (d). K = Lys, A = Ala, X = E (Glu), Ac-E (Ac-
Glu) or Suc-E (Suc-Glu).  
 
Figure 9: Structure of calpain substrate – heptaarginine (CPP) conjugate labelled with two 
FRET-partner fluorophores [N-terminal Dabcyl and EDANS attached to the side chain of Glu 
(E)] (a), internalization of the free and CPP-conjugated substrates by COST cells (b), cleavage 
of the labelled substrate-CPP conjugate by calpain in S2 cell lysate with/without Ca
2+
 and 
specific enzyme inhibitor (c).  
 
 
